The estimated Net Worth of Dino Dina is at least $5.41 Milión dollars as of 25 January 2012. Dino Dina owns over 199,998 units of Dynavax Technologies stock worth over $5,408,862 and over the last 20 years Dino sold DVAX stock worth over $0.
Dino has made over 2 trades of the Dynavax Technologies stock since 2011, according to the Form 4 filled with the SEC. Most recently Dino exercised 199,998 units of DVAX stock worth $599,994 on 25 January 2012.
The largest trade Dino's ever made was exercising 199,998 units of Dynavax Technologies stock on 25 January 2012 worth over $599,994. On average, Dino trades about 17,059 units every 4 days since 2005. As of 25 January 2012 Dino still owns at least 495,771 units of Dynavax Technologies stock.
You can see the complete history of Dino Dina stock trades at the bottom of the page.
Dino's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, BERKELEY, CA, 94710.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... a James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: